For the Inventor, By the Inventor

Enter assignee name

Neovacs

USPTO Granted Patents = 21

% Expired Patents = 28.6

CIPO Patents = 2

EPO Patents = 7

Trademarks = 2

Forward Citations = 89

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

Daniel Zagury (17 out of 25 patents)

Bernard Bizzini (7 out of 9 patents)

Jean-François Zagury (3 out of 6 patents)

4. Hélène Le Buanec (3 out of 3 patents)

5. Helene Le Buanec (2 out of 4 patents)

6. Jay F Rappaport (2 out of 7 patents)

7. Jean-Francois Zagury (2 out of 13 patents)

8. Helene Le Buannec (2 out of 2 patents)

9. Miguel Carcagno (2 out of 2 patents)

10. Jean-François Zagury (2 out of 2 patents)

11. Jean-Francedillaois Zagury (2 out of 2 patents)

12. Géraldine Grouard-vogel (2 out of 2 patents)

13. Noémie Caillot (1 out of 2 patents)

14. Vincent Serra (1 out of 7 patents)

15. Pierre Vandepapeliere (1 out of 4 patents)

21 patents: Sort by Forward Citations

1. 12059457 - Immunogenic product comprising IL-4 and/or IL-13 for treating disorders associated with aberrant IL-4 and/or IL 13 expression or activity (2024-08-13),

2. 9993565 - Method for treating IFNalpha related conditions (2018-06-12),

3. 8697047 - Stable immunogenic product comprising antigenic heterocomplexes (2014-04-15),

4. 8679483 - High-yield method for the production of human antibodies blocking the biological activity of a human cytokine (2014-03-25),

5. 8372388 - Method for preparing a stable TNF-α vaccine (2013-02-12),

6. 8101165 - Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors (2012-01-24),

7. 7972603 - Stable immunogenic product comprising antigenic heterocomplexes (2011-07-05),

8. 7887811 - Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein (2011-02-15),

9. 7504479 - Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses (2009-03-17),

10. 7351554 - Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's (2008-04-01),

11. 7314629 - Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus (2008-01-01),

12. 7022482 - Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses (2006-04-04),

13. 7022326 - Carboxymethylated retroviral regulatory proteins and interferon-α (2006-04-04),

14. 7015016 - Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's (2006-03-21),

15. 6878370 - Chemically modified TNF-α (2005-04-12),

Company Overview

Neovacs is a biotechnology company based in Paris, specializing in the development of innovative therapeutic solutions for autoimmune diseases and allergies. The company focuses on its proprietary platform technology, which utilizes the body's immune system to create targeted treatments. Neovacs is dedicated to advancing research in immunotherapy, aiming to provide effective and personalized healthcare solutions. With a commitment to scientific excellence, the company collaborates with various research institutions to enhance its therapeutic offerings.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

21 Patents

#229 in Paris

#971 in France

#29,928 in the World

Neovacs

Forward Citations = 89

26 inventors:

Daniel Zagury (17 out of 25 patents)

Bernard Bizzini (7 out of 9 patents)

Jean-François Zagury (3 out of 6 patents)

4. Hélène Le Buanec (3 out of 3 patents)

5. Helene Le Buanec (2 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Neovacs. Retrieved from https://idiyas.com/company/neovacs

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…